Advertisement

U.S. markets open in 14 minutes

S&P Futures
4,253.00
-28.00(-0.65%)
Dow Futures
33,514.00
-204.00(-0.61%)
Nasdaq Futures
13,516.50
-61.25(-0.45%)
Russell 2000 Futures
2,000.60
-16.30(-0.81%)
Crude Oil
87.26
-4.83(-5.24%)
Gold
1,792.90
-22.60(-1.24%)

Advertisement

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

50.11

+1.82

(+3.77%)

At close: 04:04PM EDT

49.85

-0.26

(-0.52%)

Pre-Market:

09:13AM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Hammer

View all chart patterns

Performance Outlook

Previous Close	48.29
Open	48.55
Bid	49.85 x 900
Ask	49.95 x 1200
Day's Range	48.55 - 50.39
52 Week Range	40.94 - 61.71
Volume	25,835,465
Avg. Volume	20,818,059

Market Cap	281.235B
Beta (5Y Monthly)	0.62
PE Ratio (TTM)	9.75
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	1.60 (3.19%)
Ex-Dividend Date	Jul 28, 2022
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

-6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PFE

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Pfizer, Inc.
Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
Rating
Fair Value
Economic Moat
4 days agoArgus Research

News

MarketWatch
Pfizer CEO tests positive for COVID-19
MARKET PULSE Pfizer Inc. (pfe) CEO Albert Bourla tested positive for COVID-19. He tweeted Monday that he received four shots of the COVID-19 vaccine the company developed with BioNTech SE (bntx) is "experiencing very mild symptoms" and has started taking Paxlovid, Pfizer's COVID-19 antiviral.
- Pfizer CEO Bourla shows mild symptoms after testing positive for COVID
  Reuters
- Pfizer CEO Bourla Has Mild Case of Covid-19
  Barrons.com
Barrons.com
Pfizer CEO Bourla Has Mild Case of Covid-19
The Pfizer CEO says he has received four doses of his company’s Covid-19 vaccine. Albert Bourla said he had begun taking a course of Paxlovid, his company’s Covid-19 antiviral.
- Pfizer CEO Bourla shows mild symptoms after testing positive for COVID
  Reuters
- Pfizer CEO tests positive for COVID-19
  MarketWatch
Reuters
UPDATE 2-Pfizer CEO Bourla shows mild symptoms after testing positive for COVID
Pfizer Inc Chief Executive Officer Albert Bourla said on Monday he had tested positive for COVID-19 and was experiencing very mild symptoms. Bourla, 60, said he had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid, and was isolating and following all public health precautions. "I am confident that I will have a speedy recovery," Bourla said in a statement.